nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylergometrine—Ergolines—Bromocriptine—type 2 diabetes mellitus	0.363	1	CiPCiCtD
Methylergometrine—Bromocriptine—type 2 diabetes mellitus	0.26	1	CrCtD
Methylergometrine—HTR2C—type 2 diabetes mellitus	0.0579	0.667	CbGaD
Methylergometrine—Ergonovine—Bromocriptine—type 2 diabetes mellitus	0.053	0.347	CrCrCtD
Methylergometrine—Methysergide—Bromocriptine—type 2 diabetes mellitus	0.053	0.347	CrCrCtD
Methylergometrine—Ergotamine—Bromocriptine—type 2 diabetes mellitus	0.0468	0.307	CrCrCtD
Methylergometrine—CYP3A4—type 2 diabetes mellitus	0.0289	0.333	CbGaD
Methylergometrine—HTR2B—Bromocriptine—type 2 diabetes mellitus	0.0179	0.201	CbGbCtD
Methylergometrine—DRD1—Bromocriptine—type 2 diabetes mellitus	0.0159	0.179	CbGbCtD
Methylergometrine—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.0116	0.131	CbGbCtD
Methylergometrine—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.0105	0.118	CbGbCtD
Methylergometrine—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00501	0.0564	CbGbCtD
Methylergometrine—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00447	0.0503	CbGbCtD
Methylergometrine—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00409	0.046	CbGbCtD
Methylergometrine—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00357	0.0402	CbGbCtD
Methylergometrine—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00323	0.0364	CbGbCtD
Methylergometrine—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00245	0.0276	CbGbCtD
Methylergometrine—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00235	0.0264	CbGbCtD
Methylergometrine—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00235	0.0264	CbGbCtD
Methylergometrine—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00222	0.025	CbGbCtD
Methylergometrine—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00165	0.0186	CbGbCtD
Methylergometrine—CYP3A4—Losartan—type 2 diabetes mellitus	0.00151	0.017	CbGbCtD
Methylergometrine—HTR2A—arteriole—type 2 diabetes mellitus	0.000698	0.201	CbGeAlD
Methylergometrine—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.000445	0.128	CbGeAlD
Methylergometrine—DRD1—nerve—type 2 diabetes mellitus	0.000432	0.124	CbGeAlD
Methylergometrine—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.000299	0.0862	CbGeAlD
Methylergometrine—HTR2A—hindlimb—type 2 diabetes mellitus	0.000277	0.0797	CbGeAlD
Methylergometrine—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.000216	0.0622	CbGeAlD
Methylergometrine—HTR2A—artery—type 2 diabetes mellitus	0.00017	0.0489	CbGeAlD
Methylergometrine—HTR2A—nerve—type 2 diabetes mellitus	0.000168	0.0485	CbGeAlD
Methylergometrine—HTR2A—endothelium—type 2 diabetes mellitus	0.000143	0.0413	CbGeAlD
Methylergometrine—HTR2B—cardiovascular system—type 2 diabetes mellitus	0.00011	0.0318	CbGeAlD
Methylergometrine—Ergonovine—HTR2C—type 2 diabetes mellitus	0.000108	0.109	CrCbGaD
Methylergometrine—HTR2B—cortex of kidney—type 2 diabetes mellitus	0.000105	0.0303	CbGeAlD
Methylergometrine—HTR2B—adipose tissue—type 2 diabetes mellitus	9.73e-05	0.028	CbGeAlD
Methylergometrine—Vomiting—Chlorpropamide—type 2 diabetes mellitus	9.29e-05	0.00358	CcSEcCtD
Methylergometrine—Anaphylactic shock—Pioglitazone—type 2 diabetes mellitus	9.28e-05	0.00357	CcSEcCtD
Methylergometrine—Abdominal pain—Repaglinide—type 2 diabetes mellitus	9.26e-05	0.00356	CcSEcCtD
Methylergometrine—Diarrhoea—Nateglinide—type 2 diabetes mellitus	9.26e-05	0.00356	CcSEcCtD
Methylergometrine—Rash—Tolazamide—type 2 diabetes mellitus	9.21e-05	0.00355	CcSEcCtD
Methylergometrine—Rash—Chlorpropamide—type 2 diabetes mellitus	9.21e-05	0.00355	CcSEcCtD
Methylergometrine—Headache—Chlorpropamide—type 2 diabetes mellitus	9.15e-05	0.00352	CcSEcCtD
Methylergometrine—Headache—Tolazamide—type 2 diabetes mellitus	9.15e-05	0.00352	CcSEcCtD
Methylergometrine—Rash—Linagliptin—type 2 diabetes mellitus	9.11e-05	0.00351	CcSEcCtD
Methylergometrine—Dermatitis—Linagliptin—type 2 diabetes mellitus	9.11e-05	0.00351	CcSEcCtD
Methylergometrine—Nervous system disorder—Pioglitazone—type 2 diabetes mellitus	9.1e-05	0.00351	CcSEcCtD
Methylergometrine—Angina pectoris—Irbesartan—type 2 diabetes mellitus	9.06e-05	0.00349	CcSEcCtD
Methylergometrine—Headache—Linagliptin—type 2 diabetes mellitus	9.06e-05	0.00349	CcSEcCtD
Methylergometrine—Anaphylactic shock—Glimepiride—type 2 diabetes mellitus	9.04e-05	0.00348	CcSEcCtD
Methylergometrine—Anaphylactic shock—Sitagliptin—type 2 diabetes mellitus	9.01e-05	0.00347	CcSEcCtD
Methylergometrine—Hyperhidrosis—Pioglitazone—type 2 diabetes mellitus	8.97e-05	0.00346	CcSEcCtD
Methylergometrine—Dizziness—Nateglinide—type 2 diabetes mellitus	8.95e-05	0.00345	CcSEcCtD
Methylergometrine—Vomiting—Acarbose—type 2 diabetes mellitus	8.92e-05	0.00344	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Ramipril—type 2 diabetes mellitus	8.86e-05	0.00341	CcSEcCtD
Methylergometrine—Rash—Acarbose—type 2 diabetes mellitus	8.85e-05	0.00341	CcSEcCtD
Methylergometrine—Nervous system disorder—Sitagliptin—type 2 diabetes mellitus	8.84e-05	0.0034	CcSEcCtD
Methylergometrine—Dermatitis—Acarbose—type 2 diabetes mellitus	8.84e-05	0.0034	CcSEcCtD
Methylergometrine—Tachycardia—Glimepiride—type 2 diabetes mellitus	8.83e-05	0.0034	CcSEcCtD
Methylergometrine—Tinnitus—Gliclazide—type 2 diabetes mellitus	8.79e-05	0.00338	CcSEcCtD
Methylergometrine—Hyperhidrosis—Glimepiride—type 2 diabetes mellitus	8.74e-05	0.00337	CcSEcCtD
Methylergometrine—Paraesthesia—Glipizide—type 2 diabetes mellitus	8.7e-05	0.00335	CcSEcCtD
Methylergometrine—Nausea—Chlorpropamide—type 2 diabetes mellitus	8.68e-05	0.00334	CcSEcCtD
Methylergometrine—Nausea—Tolazamide—type 2 diabetes mellitus	8.68e-05	0.00334	CcSEcCtD
Methylergometrine—Convulsion—Bromocriptine—type 2 diabetes mellitus	8.66e-05	0.00333	CcSEcCtD
Methylergometrine—Dyspnoea—Glipizide—type 2 diabetes mellitus	8.64e-05	0.00333	CcSEcCtD
Methylergometrine—Hypertension—Bromocriptine—type 2 diabetes mellitus	8.63e-05	0.00332	CcSEcCtD
Methylergometrine—Vomiting—Nateglinide—type 2 diabetes mellitus	8.6e-05	0.00331	CcSEcCtD
Methylergometrine—Rash—Nateglinide—type 2 diabetes mellitus	8.53e-05	0.00328	CcSEcCtD
Methylergometrine—Dermatitis—Nateglinide—type 2 diabetes mellitus	8.52e-05	0.00328	CcSEcCtD
Methylergometrine—Angina pectoris—Losartan—type 2 diabetes mellitus	8.52e-05	0.00328	CcSEcCtD
Methylergometrine—Hypotension—Glimepiride—type 2 diabetes mellitus	8.45e-05	0.00325	CcSEcCtD
Methylergometrine—Nausea—Acarbose—type 2 diabetes mellitus	8.34e-05	0.00321	CcSEcCtD
Methylergometrine—Dyspnoea—Pioglitazone—type 2 diabetes mellitus	8.28e-05	0.00319	CcSEcCtD
Methylergometrine—Paraesthesia—Glimepiride—type 2 diabetes mellitus	8.12e-05	0.00313	CcSEcCtD
Methylergometrine—Dyspnoea—Glimepiride—type 2 diabetes mellitus	8.06e-05	0.0031	CcSEcCtD
Methylergometrine—Nausea—Nateglinide—type 2 diabetes mellitus	8.04e-05	0.00309	CcSEcCtD
Methylergometrine—Cardiac disorder—Valsartan—type 2 diabetes mellitus	8.04e-05	0.00309	CcSEcCtD
Methylergometrine—Bradycardia—Metformin—type 2 diabetes mellitus	8.03e-05	0.00309	CcSEcCtD
Methylergometrine—Diarrhoea—Repaglinide—type 2 diabetes mellitus	8.01e-05	0.00309	CcSEcCtD
Methylergometrine—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	8e-05	0.00308	CcSEcCtD
Methylergometrine—Tachycardia—Bromocriptine—type 2 diabetes mellitus	7.96e-05	0.00307	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Glipizide—type 2 diabetes mellitus	7.92e-05	0.00305	CcSEcCtD
Methylergometrine—Pergolide—ADRA2A—type 2 diabetes mellitus	7.92e-05	0.0799	CrCbGaD
Methylergometrine—Convulsion—Glyburide—type 2 diabetes mellitus	7.92e-05	0.00305	CcSEcCtD
Methylergometrine—Methysergide—HTR2C—type 2 diabetes mellitus	7.88e-05	0.0794	CrCbGaD
Methylergometrine—Abdominal pain—Glipizide—type 2 diabetes mellitus	7.66e-05	0.00295	CcSEcCtD
Methylergometrine—Hypotension—Bromocriptine—type 2 diabetes mellitus	7.62e-05	0.00293	CcSEcCtD
Methylergometrine—Bradycardia—Irbesartan—type 2 diabetes mellitus	7.58e-05	0.00292	CcSEcCtD
Methylergometrine—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	7.57e-05	0.00292	CcSEcCtD
Methylergometrine—Vomiting—Repaglinide—type 2 diabetes mellitus	7.45e-05	0.00287	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	7.39e-05	0.00285	CcSEcCtD
Methylergometrine—Rash—Repaglinide—type 2 diabetes mellitus	7.38e-05	0.00284	CcSEcCtD
Methylergometrine—Dermatitis—Repaglinide—type 2 diabetes mellitus	7.38e-05	0.00284	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	7.37e-05	0.00284	CcSEcCtD
Methylergometrine—Headache—Repaglinide—type 2 diabetes mellitus	7.34e-05	0.00282	CcSEcCtD
Methylergometrine—Paraesthesia—Bromocriptine—type 2 diabetes mellitus	7.33e-05	0.00282	CcSEcCtD
Methylergometrine—Dizziness—Rosiglitazone—type 2 diabetes mellitus	7.32e-05	0.00282	CcSEcCtD
Methylergometrine—Cardiac disorder—Metformin—type 2 diabetes mellitus	7.32e-05	0.00282	CcSEcCtD
Methylergometrine—Nervous system disorder—Glyburide—type 2 diabetes mellitus	7.31e-05	0.00282	CcSEcCtD
Methylergometrine—Sweating increased—Ramipril—type 2 diabetes mellitus	7.31e-05	0.00281	CcSEcCtD
Methylergometrine—Angina pectoris—Ramipril—type 2 diabetes mellitus	7.31e-05	0.00281	CcSEcCtD
Methylergometrine—Pergolide—HTR2C—type 2 diabetes mellitus	7.29e-05	0.0735	CrCbGaD
Methylergometrine—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	7.27e-05	0.0028	CcSEcCtD
Methylergometrine—Palpitations—Gliclazide—type 2 diabetes mellitus	7.25e-05	0.00279	CcSEcCtD
Methylergometrine—Muscle spasms—Valsartan—type 2 diabetes mellitus	7.25e-05	0.00279	CcSEcCtD
Methylergometrine—Hyperhidrosis—Glyburide—type 2 diabetes mellitus	7.21e-05	0.00278	CcSEcCtD
Methylergometrine—Muscle spasms—Orlistat—type 2 diabetes mellitus	7.16e-05	0.00276	CcSEcCtD
Methylergometrine—Abdominal pain—Glimepiride—type 2 diabetes mellitus	7.15e-05	0.00275	CcSEcCtD
Methylergometrine—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	7.13e-05	0.00274	CcSEcCtD
Methylergometrine—Convulsion—Gliclazide—type 2 diabetes mellitus	7.11e-05	0.00274	CcSEcCtD
Methylergometrine—Hypertension—Gliclazide—type 2 diabetes mellitus	7.08e-05	0.00273	CcSEcCtD
Methylergometrine—Chest pain—Gliclazide—type 2 diabetes mellitus	6.99e-05	0.00269	CcSEcCtD
Methylergometrine—Rash—Rosiglitazone—type 2 diabetes mellitus	6.98e-05	0.00269	CcSEcCtD
Methylergometrine—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	6.97e-05	0.00268	CcSEcCtD
Methylergometrine—Hypotension—Glyburide—type 2 diabetes mellitus	6.97e-05	0.00268	CcSEcCtD
Methylergometrine—HTR2A—retina—type 2 diabetes mellitus	6.96e-05	0.0201	CbGeAlD
Methylergometrine—Nausea—Repaglinide—type 2 diabetes mellitus	6.96e-05	0.00268	CcSEcCtD
Methylergometrine—Tinnitus—Irbesartan—type 2 diabetes mellitus	6.94e-05	0.00267	CcSEcCtD
Methylergometrine—Headache—Rosiglitazone—type 2 diabetes mellitus	6.93e-05	0.00267	CcSEcCtD
Methylergometrine—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	6.91e-05	0.00266	CcSEcCtD
Methylergometrine—Lisuride—ADRA2A—type 2 diabetes mellitus	6.87e-05	0.0693	CrCbGaD
Methylergometrine—Paraesthesia—Glyburide—type 2 diabetes mellitus	6.7e-05	0.00258	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	6.67e-05	0.00257	CcSEcCtD
Methylergometrine—Palpitations—Valsartan—type 2 diabetes mellitus	6.66e-05	0.00256	CcSEcCtD
Methylergometrine—Dyspnoea—Glyburide—type 2 diabetes mellitus	6.65e-05	0.00256	CcSEcCtD
Methylergometrine—Diarrhoea—Glipizide—type 2 diabetes mellitus	6.63e-05	0.00255	CcSEcCtD
Methylergometrine—Ergotamine—ADRA2A—type 2 diabetes mellitus	6.6e-05	0.0666	CrCbGaD
Methylergometrine—Muscle spasms—Metformin—type 2 diabetes mellitus	6.6e-05	0.00254	CcSEcCtD
Methylergometrine—Palpitations—Orlistat—type 2 diabetes mellitus	6.58e-05	0.00253	CcSEcCtD
Methylergometrine—Nausea—Rosiglitazone—type 2 diabetes mellitus	6.57e-05	0.00253	CcSEcCtD
Methylergometrine—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	6.57e-05	0.00253	CcSEcCtD
Methylergometrine—Tachycardia—Gliclazide—type 2 diabetes mellitus	6.54e-05	0.00252	CcSEcCtD
Methylergometrine—Tinnitus—Losartan—type 2 diabetes mellitus	6.53e-05	0.00251	CcSEcCtD
Methylergometrine—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	6.47e-05	0.00249	CcSEcCtD
Methylergometrine—Convulsion—Orlistat—type 2 diabetes mellitus	6.45e-05	0.00248	CcSEcCtD
Methylergometrine—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	6.45e-05	0.00248	CcSEcCtD
Methylergometrine—Chest pain—Valsartan—type 2 diabetes mellitus	6.42e-05	0.00247	CcSEcCtD
Methylergometrine—Dizziness—Glipizide—type 2 diabetes mellitus	6.41e-05	0.00247	CcSEcCtD
Methylergometrine—Bromocriptine—ADRA2A—type 2 diabetes mellitus	6.37e-05	0.0642	CrCbGaD
Methylergometrine—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	6.35e-05	0.00245	CcSEcCtD
Methylergometrine—Chest pain—Orlistat—type 2 diabetes mellitus	6.34e-05	0.00244	CcSEcCtD
Methylergometrine—Lisuride—HTR2C—type 2 diabetes mellitus	6.33e-05	0.0638	CrCbGaD
Methylergometrine—Hypotension—Gliclazide—type 2 diabetes mellitus	6.26e-05	0.00241	CcSEcCtD
Methylergometrine—Muscle spasms—Irbesartan—type 2 diabetes mellitus	6.23e-05	0.0024	CcSEcCtD
Methylergometrine—Diarrhoea—Glimepiride—type 2 diabetes mellitus	6.19e-05	0.00238	CcSEcCtD
Methylergometrine—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	6.17e-05	0.00237	CcSEcCtD
Methylergometrine—Vomiting—Glipizide—type 2 diabetes mellitus	6.16e-05	0.00237	CcSEcCtD
Methylergometrine—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	6.15e-05	0.00237	CcSEcCtD
Methylergometrine—Dizziness—Pioglitazone—type 2 diabetes mellitus	6.14e-05	0.00236	CcSEcCtD
Methylergometrine—Rash—Glipizide—type 2 diabetes mellitus	6.11e-05	0.00235	CcSEcCtD
Methylergometrine—Dermatitis—Glipizide—type 2 diabetes mellitus	6.1e-05	0.00235	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	6.1e-05	0.00235	CcSEcCtD
Methylergometrine—Ergotamine—HTR2C—type 2 diabetes mellitus	6.08e-05	0.0613	CrCbGaD
Methylergometrine—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	6.08e-05	0.00234	CcSEcCtD
Methylergometrine—Headache—Glipizide—type 2 diabetes mellitus	6.07e-05	0.00234	CcSEcCtD
Methylergometrine—Palpitations—Metformin—type 2 diabetes mellitus	6.07e-05	0.00234	CcSEcCtD
Methylergometrine—Nervous system disorder—Valsartan—type 2 diabetes mellitus	6.03e-05	0.00232	CcSEcCtD
Methylergometrine—Paraesthesia—Gliclazide—type 2 diabetes mellitus	6.01e-05	0.00232	CcSEcCtD
Methylergometrine—Dizziness—Glimepiride—type 2 diabetes mellitus	5.98e-05	0.0023	CcSEcCtD
Methylergometrine—Dyspnoea—Gliclazide—type 2 diabetes mellitus	5.97e-05	0.0023	CcSEcCtD
Methylergometrine—Nervous system disorder—Orlistat—type 2 diabetes mellitus	5.96e-05	0.0023	CcSEcCtD
Methylergometrine—Dizziness—Sitagliptin—type 2 diabetes mellitus	5.96e-05	0.0023	CcSEcCtD
Methylergometrine—Hypertension—Metformin—type 2 diabetes mellitus	5.93e-05	0.00228	CcSEcCtD
Methylergometrine—Abdominal pain—Glyburide—type 2 diabetes mellitus	5.9e-05	0.00227	CcSEcCtD
Methylergometrine—HTR2A—cardiovascular system—type 2 diabetes mellitus	5.89e-05	0.017	CbGeAlD
Methylergometrine—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	5.88e-05	0.00226	CcSEcCtD
Methylergometrine—Bromocriptine—HTR2C—type 2 diabetes mellitus	5.86e-05	0.0591	CrCbGaD
Methylergometrine—Muscle spasms—Losartan—type 2 diabetes mellitus	5.86e-05	0.00226	CcSEcCtD
Methylergometrine—Chest pain—Metformin—type 2 diabetes mellitus	5.84e-05	0.00225	CcSEcCtD
Methylergometrine—Headache—Pioglitazone—type 2 diabetes mellitus	5.82e-05	0.00224	CcSEcCtD
Methylergometrine—HTR2A—kidney—type 2 diabetes mellitus	5.76e-05	0.0166	CbGeAlD
Methylergometrine—Nausea—Glipizide—type 2 diabetes mellitus	5.76e-05	0.00222	CcSEcCtD
Methylergometrine—Vomiting—Glimepiride—type 2 diabetes mellitus	5.75e-05	0.00221	CcSEcCtD
Methylergometrine—Hypotension—Valsartan—type 2 diabetes mellitus	5.75e-05	0.00221	CcSEcCtD
Methylergometrine—Vomiting—Sitagliptin—type 2 diabetes mellitus	5.73e-05	0.00221	CcSEcCtD
Methylergometrine—Rash—Glimepiride—type 2 diabetes mellitus	5.7e-05	0.0022	CcSEcCtD
Methylergometrine—Dermatitis—Glimepiride—type 2 diabetes mellitus	5.7e-05	0.00219	CcSEcCtD
Methylergometrine—Rash—Sitagliptin—type 2 diabetes mellitus	5.68e-05	0.00219	CcSEcCtD
Methylergometrine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	5.68e-05	0.00219	CcSEcCtD
Methylergometrine—Headache—Glimepiride—type 2 diabetes mellitus	5.66e-05	0.00218	CcSEcCtD
Methylergometrine—Headache—Sitagliptin—type 2 diabetes mellitus	5.65e-05	0.00217	CcSEcCtD
Methylergometrine—Tinnitus—Ramipril—type 2 diabetes mellitus	5.6e-05	0.00216	CcSEcCtD
Methylergometrine—Hypertension—Irbesartan—type 2 diabetes mellitus	5.59e-05	0.00215	CcSEcCtD
Methylergometrine—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	5.58e-05	0.00215	CcSEcCtD
Methylergometrine—Paraesthesia—Valsartan—type 2 diabetes mellitus	5.52e-05	0.00213	CcSEcCtD
Methylergometrine—Chest pain—Irbesartan—type 2 diabetes mellitus	5.52e-05	0.00212	CcSEcCtD
Methylergometrine—Nervous system disorder—Metformin—type 2 diabetes mellitus	5.49e-05	0.00212	CcSEcCtD
Methylergometrine—Dyspnoea—Valsartan—type 2 diabetes mellitus	5.49e-05	0.00211	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	5.48e-05	0.00211	CcSEcCtD
Methylergometrine—Paraesthesia—Orlistat—type 2 diabetes mellitus	5.46e-05	0.0021	CcSEcCtD
Methylergometrine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	5.42e-05	0.00209	CcSEcCtD
Methylergometrine—Dizziness—Bromocriptine—type 2 diabetes mellitus	5.39e-05	0.00208	CcSEcCtD
Methylergometrine—Ergonovine—CYP3A4—type 2 diabetes mellitus	5.39e-05	0.0544	CrCbGaD
Methylergometrine—Palpitations—Losartan—type 2 diabetes mellitus	5.39e-05	0.00207	CcSEcCtD
Methylergometrine—Nausea—Glimepiride—type 2 diabetes mellitus	5.37e-05	0.00207	CcSEcCtD
Methylergometrine—Nausea—Sitagliptin—type 2 diabetes mellitus	5.35e-05	0.00206	CcSEcCtD
Methylergometrine—CYP3A4—kidney—type 2 diabetes mellitus	5.34e-05	0.0154	CbGeAlD
Methylergometrine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	5.29e-05	0.00204	CcSEcCtD
Methylergometrine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	5.29e-05	0.00204	CcSEcCtD
Methylergometrine—Hypotension—Metformin—type 2 diabetes mellitus	5.24e-05	0.00202	CcSEcCtD
Methylergometrine—Chest pain—Losartan—type 2 diabetes mellitus	5.19e-05	0.002	CcSEcCtD
Methylergometrine—Vomiting—Bromocriptine—type 2 diabetes mellitus	5.19e-05	0.002	CcSEcCtD
Methylergometrine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	5.19e-05	0.002	CcSEcCtD
Methylergometrine—Tachycardia—Irbesartan—type 2 diabetes mellitus	5.16e-05	0.00199	CcSEcCtD
Methylergometrine—Rash—Bromocriptine—type 2 diabetes mellitus	5.14e-05	0.00198	CcSEcCtD
Methylergometrine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	5.14e-05	0.00198	CcSEcCtD
Methylergometrine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	5.11e-05	0.00197	CcSEcCtD
Methylergometrine—Headache—Bromocriptine—type 2 diabetes mellitus	5.11e-05	0.00197	CcSEcCtD
Methylergometrine—Diarrhoea—Glyburide—type 2 diabetes mellitus	5.1e-05	0.00196	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	5.03e-05	0.00194	CcSEcCtD
Methylergometrine—Paraesthesia—Metformin—type 2 diabetes mellitus	5.03e-05	0.00194	CcSEcCtD
Methylergometrine—Muscle spasms—Ramipril—type 2 diabetes mellitus	5.03e-05	0.00194	CcSEcCtD
Methylergometrine—Dyspnoea—Metformin—type 2 diabetes mellitus	4.99e-05	0.00192	CcSEcCtD
Methylergometrine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	4.98e-05	0.00192	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	4.97e-05	0.00191	CcSEcCtD
Methylergometrine—Hypotension—Irbesartan—type 2 diabetes mellitus	4.94e-05	0.0019	CcSEcCtD
Methylergometrine—Nervous system disorder—Losartan—type 2 diabetes mellitus	4.88e-05	0.00188	CcSEcCtD
Methylergometrine—Abdominal pain—Valsartan—type 2 diabetes mellitus	4.86e-05	0.00187	CcSEcCtD
Methylergometrine—Tachycardia—Losartan—type 2 diabetes mellitus	4.86e-05	0.00187	CcSEcCtD
Methylergometrine—Nausea—Bromocriptine—type 2 diabetes mellitus	4.85e-05	0.00187	CcSEcCtD
Methylergometrine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	4.81e-05	0.00185	CcSEcCtD
Methylergometrine—Abdominal pain—Orlistat—type 2 diabetes mellitus	4.81e-05	0.00185	CcSEcCtD
Methylergometrine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	4.75e-05	0.00183	CcSEcCtD
Methylergometrine—Vomiting—Glyburide—type 2 diabetes mellitus	4.74e-05	0.00183	CcSEcCtD
Methylergometrine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	4.71e-05	0.00181	CcSEcCtD
Methylergometrine—Rash—Glyburide—type 2 diabetes mellitus	4.7e-05	0.00181	CcSEcCtD
Methylergometrine—Dermatitis—Glyburide—type 2 diabetes mellitus	4.7e-05	0.00181	CcSEcCtD
Methylergometrine—Headache—Glyburide—type 2 diabetes mellitus	4.67e-05	0.0018	CcSEcCtD
Methylergometrine—Hypotension—Losartan—type 2 diabetes mellitus	4.65e-05	0.00179	CcSEcCtD
Methylergometrine—Palpitations—Ramipril—type 2 diabetes mellitus	4.62e-05	0.00178	CcSEcCtD
Methylergometrine—Ergotamine—CYP1A2—type 2 diabetes mellitus	4.59e-05	0.0463	CrCbGaD
Methylergometrine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	4.58e-05	0.00176	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	4.58e-05	0.00176	CcSEcCtD
Methylergometrine—Convulsion—Ramipril—type 2 diabetes mellitus	4.53e-05	0.00174	CcSEcCtD
Methylergometrine—Paraesthesia—Losartan—type 2 diabetes mellitus	4.47e-05	0.00172	CcSEcCtD
Methylergometrine—Chest pain—Ramipril—type 2 diabetes mellitus	4.45e-05	0.00171	CcSEcCtD
Methylergometrine—Dyspnoea—Losartan—type 2 diabetes mellitus	4.44e-05	0.00171	CcSEcCtD
Methylergometrine—Nausea—Glyburide—type 2 diabetes mellitus	4.43e-05	0.00171	CcSEcCtD
Methylergometrine—Abdominal pain—Metformin—type 2 diabetes mellitus	4.43e-05	0.00171	CcSEcCtD
Methylergometrine—Dizziness—Gliclazide—type 2 diabetes mellitus	4.43e-05	0.0017	CcSEcCtD
Methylergometrine—Bromocriptine—CYP1A2—type 2 diabetes mellitus	4.42e-05	0.0446	CrCbGaD
Methylergometrine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	4.32e-05	0.00166	CcSEcCtD
Methylergometrine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	4.27e-05	0.00164	CcSEcCtD
Methylergometrine—Vomiting—Gliclazide—type 2 diabetes mellitus	4.26e-05	0.00164	CcSEcCtD
Methylergometrine—Rash—Gliclazide—type 2 diabetes mellitus	4.22e-05	0.00163	CcSEcCtD
Methylergometrine—Dermatitis—Gliclazide—type 2 diabetes mellitus	4.22e-05	0.00162	CcSEcCtD
Methylergometrine—Diarrhoea—Valsartan—type 2 diabetes mellitus	4.21e-05	0.00162	CcSEcCtD
Methylergometrine—Headache—Gliclazide—type 2 diabetes mellitus	4.2e-05	0.00162	CcSEcCtD
Methylergometrine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	4.18e-05	0.00161	CcSEcCtD
Methylergometrine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	4.18e-05	0.00161	CcSEcCtD
Methylergometrine—Tachycardia—Ramipril—type 2 diabetes mellitus	4.16e-05	0.0016	CcSEcCtD
Methylergometrine—Diarrhoea—Orlistat—type 2 diabetes mellitus	4.16e-05	0.0016	CcSEcCtD
Methylergometrine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	4.12e-05	0.00159	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	4.07e-05	0.00157	CcSEcCtD
Methylergometrine—Dizziness—Valsartan—type 2 diabetes mellitus	4.07e-05	0.00157	CcSEcCtD
Methylergometrine—Dizziness—Orlistat—type 2 diabetes mellitus	4.02e-05	0.00155	CcSEcCtD
Methylergometrine—Hypotension—Ramipril—type 2 diabetes mellitus	3.99e-05	0.00153	CcSEcCtD
Methylergometrine—Nausea—Gliclazide—type 2 diabetes mellitus	3.98e-05	0.00153	CcSEcCtD
Methylergometrine—Abdominal pain—Losartan—type 2 diabetes mellitus	3.93e-05	0.00151	CcSEcCtD
Methylergometrine—Vomiting—Valsartan—type 2 diabetes mellitus	3.91e-05	0.00151	CcSEcCtD
Methylergometrine—Rash—Valsartan—type 2 diabetes mellitus	3.88e-05	0.00149	CcSEcCtD
Methylergometrine—Dermatitis—Valsartan—type 2 diabetes mellitus	3.88e-05	0.00149	CcSEcCtD
Methylergometrine—Vomiting—Orlistat—type 2 diabetes mellitus	3.87e-05	0.00149	CcSEcCtD
Methylergometrine—Headache—Valsartan—type 2 diabetes mellitus	3.85e-05	0.00148	CcSEcCtD
Methylergometrine—Diarrhoea—Metformin—type 2 diabetes mellitus	3.83e-05	0.00148	CcSEcCtD
Methylergometrine—Rash—Orlistat—type 2 diabetes mellitus	3.83e-05	0.00148	CcSEcCtD
Methylergometrine—Paraesthesia—Ramipril—type 2 diabetes mellitus	3.83e-05	0.00148	CcSEcCtD
Methylergometrine—Dermatitis—Orlistat—type 2 diabetes mellitus	3.83e-05	0.00147	CcSEcCtD
Methylergometrine—Headache—Orlistat—type 2 diabetes mellitus	3.81e-05	0.00147	CcSEcCtD
Methylergometrine—Dyspnoea—Ramipril—type 2 diabetes mellitus	3.8e-05	0.00146	CcSEcCtD
Methylergometrine—Dizziness—Metformin—type 2 diabetes mellitus	3.7e-05	0.00143	CcSEcCtD
Methylergometrine—Nausea—Valsartan—type 2 diabetes mellitus	3.65e-05	0.00141	CcSEcCtD
Methylergometrine—HTR2A—liver—type 2 diabetes mellitus	3.64e-05	0.0105	CbGeAlD
Methylergometrine—Pergolide—CYP3A4—type 2 diabetes mellitus	3.64e-05	0.0367	CrCbGaD
Methylergometrine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	3.62e-05	0.00139	CcSEcCtD
Methylergometrine—Nausea—Orlistat—type 2 diabetes mellitus	3.61e-05	0.00139	CcSEcCtD
Methylergometrine—Vomiting—Metformin—type 2 diabetes mellitus	3.56e-05	0.00137	CcSEcCtD
Methylergometrine—Rash—Metformin—type 2 diabetes mellitus	3.53e-05	0.00136	CcSEcCtD
Methylergometrine—Dermatitis—Metformin—type 2 diabetes mellitus	3.53e-05	0.00136	CcSEcCtD
Methylergometrine—Headache—Metformin—type 2 diabetes mellitus	3.51e-05	0.00135	CcSEcCtD
Methylergometrine—Dizziness—Irbesartan—type 2 diabetes mellitus	3.5e-05	0.00135	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.49e-05	0.00134	CcSEcCtD
Methylergometrine—Diarrhoea—Losartan—type 2 diabetes mellitus	3.4e-05	0.00131	CcSEcCtD
Methylergometrine—CYP3A4—liver—type 2 diabetes mellitus	3.37e-05	0.00972	CbGeAlD
Methylergometrine—Abdominal pain—Ramipril—type 2 diabetes mellitus	3.37e-05	0.0013	CcSEcCtD
Methylergometrine—Vomiting—Irbesartan—type 2 diabetes mellitus	3.36e-05	0.00129	CcSEcCtD
Methylergometrine—Rash—Irbesartan—type 2 diabetes mellitus	3.33e-05	0.00128	CcSEcCtD
Methylergometrine—Dermatitis—Irbesartan—type 2 diabetes mellitus	3.33e-05	0.00128	CcSEcCtD
Methylergometrine—Nausea—Metformin—type 2 diabetes mellitus	3.33e-05	0.00128	CcSEcCtD
Methylergometrine—Headache—Irbesartan—type 2 diabetes mellitus	3.31e-05	0.00128	CcSEcCtD
Methylergometrine—Dizziness—Losartan—type 2 diabetes mellitus	3.29e-05	0.00127	CcSEcCtD
Methylergometrine—Vomiting—Losartan—type 2 diabetes mellitus	3.16e-05	0.00122	CcSEcCtD
Methylergometrine—Lisuride—CYP3A4—type 2 diabetes mellitus	3.16e-05	0.0319	CrCbGaD
Methylergometrine—Nausea—Irbesartan—type 2 diabetes mellitus	3.14e-05	0.00121	CcSEcCtD
Methylergometrine—Rash—Losartan—type 2 diabetes mellitus	3.14e-05	0.00121	CcSEcCtD
Methylergometrine—Dermatitis—Losartan—type 2 diabetes mellitus	3.13e-05	0.00121	CcSEcCtD
Methylergometrine—Headache—Losartan—type 2 diabetes mellitus	3.12e-05	0.0012	CcSEcCtD
Methylergometrine—Ergotamine—CYP3A4—type 2 diabetes mellitus	3.04e-05	0.0306	CrCbGaD
Methylergometrine—Nausea—Losartan—type 2 diabetes mellitus	2.96e-05	0.00114	CcSEcCtD
Methylergometrine—Bromocriptine—CYP3A4—type 2 diabetes mellitus	2.93e-05	0.0295	CrCbGaD
Methylergometrine—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.92e-05	0.00112	CcSEcCtD
Methylergometrine—Dizziness—Ramipril—type 2 diabetes mellitus	2.82e-05	0.00109	CcSEcCtD
Methylergometrine—Vomiting—Ramipril—type 2 diabetes mellitus	2.71e-05	0.00104	CcSEcCtD
Methylergometrine—Rash—Ramipril—type 2 diabetes mellitus	2.69e-05	0.00104	CcSEcCtD
Methylergometrine—Dermatitis—Ramipril—type 2 diabetes mellitus	2.69e-05	0.00103	CcSEcCtD
Methylergometrine—Headache—Ramipril—type 2 diabetes mellitus	2.67e-05	0.00103	CcSEcCtD
Methylergometrine—Nausea—Ramipril—type 2 diabetes mellitus	2.53e-05	0.000976	CcSEcCtD
Methylergometrine—HTR2A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.78e-06	9.85e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.78e-06	9.83e-05	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.77e-06	9.8e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.77e-06	9.76e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—C3—type 2 diabetes mellitus	1.77e-06	9.76e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.75e-06	9.7e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.75e-06	9.68e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.75e-06	9.68e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.74e-06	9.61e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.73e-06	9.59e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.73e-06	9.58e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.73e-06	9.58e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.73e-06	9.58e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.72e-06	9.52e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.72e-06	9.49e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AVP—type 2 diabetes mellitus	1.71e-06	9.48e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.71e-06	9.48e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.71e-06	9.44e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.7e-06	9.42e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.7e-06	9.4e-05	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.69e-06	9.36e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.68e-06	9.31e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.68e-06	9.3e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.68e-06	9.29e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.68e-06	9.29e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—AGT—type 2 diabetes mellitus	1.68e-06	9.28e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.68e-06	9.27e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.67e-06	9.21e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—C3—type 2 diabetes mellitus	1.66e-06	9.21e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.66e-06	9.19e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	1.66e-06	9.19e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	1.66e-06	9.19e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—APOB—type 2 diabetes mellitus	1.66e-06	9.16e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.65e-06	9.12e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.65e-06	9.12e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—LEP—type 2 diabetes mellitus	1.64e-06	9.09e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—APOE—type 2 diabetes mellitus	1.64e-06	9.09e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.64e-06	9.06e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.63e-06	9.02e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.63e-06	9.01e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.62e-06	8.98e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.61e-06	8.9e-05	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.61e-06	8.89e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	1.6e-06	8.84e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	1.6e-06	8.84e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.59e-06	8.78e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.58e-06	8.76e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.58e-06	8.76e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—AGT—type 2 diabetes mellitus	1.58e-06	8.75e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—LPL—type 2 diabetes mellitus	1.58e-06	8.75e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	1.57e-06	8.69e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.57e-06	8.67e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.56e-06	8.6e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—APOE—type 2 diabetes mellitus	1.55e-06	8.57e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—LEP—type 2 diabetes mellitus	1.55e-06	8.57e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.55e-06	8.57e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.55e-06	8.56e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—SRC—type 2 diabetes mellitus	1.55e-06	8.56e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	1.54e-06	8.54e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	1.54e-06	8.54e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	1.54e-06	8.54e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.54e-06	8.5e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.53e-06	8.47e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.52e-06	8.42e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.51e-06	8.34e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.51e-06	8.34e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AVP—type 2 diabetes mellitus	1.49e-06	8.23e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.49e-06	8.23e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.48e-06	8.21e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.48e-06	8.19e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.48e-06	8.16e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.47e-06	8.11e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.46e-06	8.08e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—SRC—type 2 diabetes mellitus	1.46e-06	8.08e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.46e-06	8.07e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.46e-06	8.06e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	1.45e-06	8.03e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—APOB—type 2 diabetes mellitus	1.44e-06	7.96e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.43e-06	7.92e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—C3—type 2 diabetes mellitus	1.42e-06	7.88e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.42e-06	7.87e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.42e-06	7.83e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—INS—type 2 diabetes mellitus	1.4e-06	7.76e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.38e-06	7.65e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.38e-06	7.65e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.38e-06	7.64e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—LPL—type 2 diabetes mellitus	1.37e-06	7.6e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	1.36e-06	7.52e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.36e-06	7.51e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.36e-06	7.51e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.36e-06	7.5e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.36e-06	7.5e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.35e-06	7.49e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AGT—type 2 diabetes mellitus	1.35e-06	7.48e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.35e-06	7.47e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.34e-06	7.44e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.33e-06	7.36e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—APOE—type 2 diabetes mellitus	1.33e-06	7.33e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—LEP—type 2 diabetes mellitus	1.33e-06	7.33e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—INS—type 2 diabetes mellitus	1.32e-06	7.32e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	1.31e-06	7.26e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	1.31e-06	7.26e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	1.31e-06	7.26e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	1.31e-06	7.26e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.31e-06	7.25e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.31e-06	7.22e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.3e-06	7.2e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.29e-06	7.13e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.29e-06	7.13e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.28e-06	7.08e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.28e-06	7.08e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.28e-06	7.08e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.27e-06	7.05e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.27e-06	7e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	1.26e-06	6.96e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.25e-06	6.91e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—C3—type 2 diabetes mellitus	1.24e-06	6.84e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.23e-06	6.81e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.23e-06	6.81e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.22e-06	6.73e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.18e-06	6.54e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.18e-06	6.52e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.18e-06	6.51e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AGT—type 2 diabetes mellitus	1.18e-06	6.5e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.17e-06	6.47e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.16e-06	6.42e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.16e-06	6.42e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—RELA—type 2 diabetes mellitus	1.16e-06	6.41e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.16e-06	6.39e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—APOE—type 2 diabetes mellitus	1.15e-06	6.37e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—LEP—type 2 diabetes mellitus	1.15e-06	6.37e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.14e-06	6.29e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—INS—type 2 diabetes mellitus	1.13e-06	6.26e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.11e-06	6.16e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.1e-06	6.06e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.09e-06	6.05e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.09e-06	6.04e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.09e-06	6.04e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.09e-06	6.03e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.09e-06	6e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.07e-06	5.92e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.07e-06	5.92e-05	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.05e-06	5.83e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.05e-06	5.81e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.05e-06	5.78e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.04e-06	5.77e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.04e-06	5.77e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.04e-06	5.77e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—IL6—type 2 diabetes mellitus	1.04e-06	5.77e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.04e-06	5.75e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.04e-06	5.74e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.04e-06	5.73e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.03e-06	5.68e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.02e-06	5.63e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.01e-06	5.57e-05	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.95e-07	5.5e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	9.93e-07	5.49e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	9.93e-07	5.49e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.88e-07	5.46e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.86e-07	5.45e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—IL6—type 2 diabetes mellitus	9.84e-07	5.44e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—INS—type 2 diabetes mellitus	9.84e-07	5.44e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.79e-07	5.42e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.77e-07	5.4e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	9.68e-07	5.35e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.62e-07	5.32e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.58e-07	5.3e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	9.51e-07	5.26e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	9.51e-07	5.26e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	9.47e-07	5.24e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	9.36e-07	5.18e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	9.36e-07	5.18e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	9.36e-07	5.18e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—RELA—type 2 diabetes mellitus	9.35e-07	5.17e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.31e-07	5.15e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.22e-07	5.1e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	9.19e-07	5.08e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SRC—type 2 diabetes mellitus	9.11e-07	5.04e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	9.1e-07	5.03e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.08e-07	5.02e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.03e-07	5e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	9.03e-07	5e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	8.91e-07	4.93e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.87e-07	4.91e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.63e-07	4.77e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.63e-07	4.77e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	8.59e-07	4.75e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	8.56e-07	4.73e-05	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	8.51e-07	4.71e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	8.46e-07	4.68e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	8.46e-07	4.68e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.43e-07	4.66e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	8.38e-07	4.63e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.36e-07	4.63e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.14e-07	4.5e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	8.12e-07	4.49e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	8.11e-07	4.49e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	8.11e-07	4.49e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.98e-07	4.41e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.97e-07	4.41e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.88e-07	4.36e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	7.73e-07	4.27e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.68e-07	4.25e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.53e-07	4.16e-05	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	7.39e-07	4.09e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	7.35e-07	4.06e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.32e-07	4.05e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	7.28e-07	4.02e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.16e-07	3.96e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	6.99e-07	3.87e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.99e-07	3.87e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	6.96e-07	3.85e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.92e-07	3.83e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	6.87e-07	3.8e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.85e-07	3.79e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.71e-07	3.71e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	6.67e-07	3.69e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.57e-07	3.63e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	6.49e-07	3.59e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.44e-07	3.56e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	6.38e-07	3.53e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	6.37e-07	3.52e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	6.23e-07	3.45e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.21e-07	3.44e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	6.21e-07	3.44e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL6—type 2 diabetes mellitus	6.13e-07	3.39e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	6.05e-07	3.35e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	5.97e-07	3.3e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.79e-07	3.2e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	5.73e-07	3.17e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.7e-07	3.15e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.66e-07	3.13e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	5.62e-07	3.11e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.59e-07	3.09e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	5.45e-07	3.01e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	5.36e-07	2.96e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.34e-07	2.95e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	5.34e-07	2.95e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	5.28e-07	2.92e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	4.95e-07	2.74e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	4.65e-07	2.57e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.57e-07	2.53e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	4.56e-07	2.52e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	4.3e-07	2.38e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	4.18e-07	2.31e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	4e-07	2.21e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	4e-07	2.21e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.96e-07	2.19e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	3.66e-07	2.02e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.84e-07	1.02e-05	CbGpPWpGaD
